Eversept Partners’s Protagonist Therapeutics PTGX Stock Holding History

Eversept Partners’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-52,961	Closed	-$4.63M	–	143
2025 Q4	$4.63M	Buy	+52,961	New	+$4.33M	0.23%	72
2025 Q3	–	Sell	-277,316	Closed	-$15.3M	–	98
2025 Q2	$15.3M	Sell	277,316 -269,800	-49%	-$12.9M	1.41%	26
2025 Q1	$26.5M	Sell	547,116 -131,671	-19%	-$5.52M	2.69%	11
2024 Q4	$26.2M	Buy	678,787 +233,583	+52%	+$10.2M	2.33%	11
2024 Q3	$20M	Sell	445,204 -60,632	-12%	-$2.45M	1.37%	19
2024 Q2	$17.5M	Buy	505,836 +94,358	+23%	+$2.76M	1.2%	20
2024 Q1	$11.9M	Sell	411,478 -126,596	-24%	-$3.44M	0.79%	24
2023 Q4	$12.3M	Buy	538,074 +251,326	+88%	+$4.4M	1.08%	22
2023 Q3	$4.78M	Buy	286,748 +172,089	+150%	+$3.34M	0.4%	42
2023 Q2	$3.17M	Buy	+114,659	New	+$2.87M	0.26%	51

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Eversept Partners's PTGX Position: Q1 2026 in Review

Eversept Partners sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 52,961 shares — an estimated $4.63M sold.

Eversept Partners first reported a position in PTGX in Q2 2023 and held it in 10 quarters. The position peaked at $26.5M in Q1 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Eversept Partners reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
Eversept Partners sold 52,961 Protagonist Therapeutics shares in Q1 2026, an estimated $4.63M.
Eversept Partners first reported a position in Protagonist Therapeutics in Q2 2023 and held it in 10 quarters.
Eversept Partners's Protagonist Therapeutics position peaked at $26.5M in Q1 2025.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.